Johnson & Johnson Quick Ratio 2010-2022 | JNJ

Historical quick ratio values for Johnson & Johnson (JNJ) over the last 10 years.
Johnson & Johnson Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-06-30 $52.41B $44.82B 1.17
2022-03-31 $49.43B $43.39B 1.14
2021-12-31 $50.59B $45.23B 1.12
2021-09-30 $49.50B $44.56B 1.11
2021-06-30 $43.67B $38.72B 1.13
2021-03-31 $42.58B $40.93B 1.04
2020-12-31 $41.89B $42.49B 0.99
2020-09-30 $47.98B $38.85B 1.24
2020-06-30 $36.47B $36.77B 0.99
2020-03-31 $35.36B $33.69B 1.05
2019-12-31 $36.25B $35.96B 1.01
2019-09-30 $35.16B $35.16B 1.00
2019-06-30 $32.54B $31.35B 1.04
2019-03-31 $32.90B $29.11B 1.13
2018-12-31 $37.43B $31.23B 1.20
2018-09-30 $38.52B $27.44B 1.40
2018-06-30 $36.63B $27.49B 1.33
2018-03-31 $33.75B $27.08B 1.25
2017-12-31 $34.32B $30.54B 1.12
2017-09-30 $32.31B $31.81B 1.02
2017-06-30 $29.09B $28.87B 1.01
2017-03-31 $54.47B $25.12B 2.17
2016-12-31 $56.89B $26.29B 2.16
2016-09-30 $54.83B $23.23B 2.36
2016-06-30 $57.77B $21.54B 2.68
2016-03-31 $54.57B $22.13B 2.47
2015-12-31 $52.16B $27.75B 1.88
2015-09-30 $55.29B $25.26B 2.19
2015-06-30 $52.70B $24.51B 2.15
2015-03-31 $50.11B $23.84B 2.10
2014-12-31 $47.56B $25.03B 1.90
2014-09-30 $51.55B $22.98B 2.24
2014-06-30 $51.96B $24.36B 2.13
2014-03-31 $49.36B $23.84B 2.07
2013-12-31 $48.53B $25.68B 1.89
2013-09-30 $44.05B $25.84B 1.71
2013-06-30 $43.45B $23.77B 1.83
2013-03-31 $39.54B $22.52B 1.76
2012-12-31 $38.62B $24.26B 1.59
2012-09-30 $36.98B $23.94B 1.55
2012-06-30 $33.92B $23.85B 1.42
2012-03-31 $50.21B $21.20B 2.37
2011-12-31 $48.03B $22.81B 2.11
2011-09-30 $47.02B $21.69B 2.17
2011-06-30 $46.26B $20.99B 2.20
2011-03-31 $43.02B $24.01B 1.79
2010-12-31 $41.93B $23.07B 1.82
2010-09-30 $37.31B $17.41B 2.14
2010-06-30 $33.95B $17.16B 1.98
2010-03-31 $33.55B $18.50B 1.81
2009-12-31 $34.36B $21.73B 1.58
2009-09-30 $30.03B $19.25B 1.56
2009-06-30 $30.02B $19.89B 1.51
2009-03-31 $29.48B $21.33B 1.38
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $435.655B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17